TNGX — Tango Therapeutics, Inc. stock price, charts and financials

Latest market price

27.21

+0.03+0.11%

Overview Short InterestFilings

TNGXQT79Tango Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

27.21+0.11%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TLX+1.31%$10.02 IDYA-0.28%$35.40 ARQT-3.43%$25.94 LEGN+2.48%$19.01 RLAY-0.27%$18.78 ALMS-7.54%$26.12 NAMS-1.08%$27.49 RCUS-2.02%$27.62

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.91	Insider Own	-	Shs Outstand	124.44M	Perf Week	2.07%

Market Cap	3.38B	Forward P/E	-	EPS next Y	-1.49	Insider Trans	-0.41%	Shs Float	82.01M	Perf Month	-5.40%

Enterprise Value	3.26B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	52.09%	Perf Quarter	25.72%

Income	-93.01M	P/S	59.34	EPS this Y	-41.42%	Inst Trans	-	Short Ratio	10.25	Perf Half Y	132.90%

Sales	56.99M	P/B	9.97	EPS next Y	-15.72%	ROA	-24.61%	Short Interest	42.72M	Perf YTD	206.77%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-41.54%	52W High	34.43 -20.97%	Perf Year	331.43%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-27.69%	52W Low	5.78 371.06%	Perf 3Y	815.15%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	35.36% 50.61%	Gross Margin	97.25%	Volatility	5.97% 5.95%	Perf 5Y	158.61%

Dividend TTM	-	EV/Sales	57.15	EPS Y/Y TTM	23.53%	Oper. Margin	-206.22%	ATR (14)	1.82	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	27.38	Sales Y/Y TTM	57.14%	Profit Margin	-188.15%	RSI (14)	46.97	Recom	2.08

Dividend Gr. 3/5Y	-	Current Ratio	27.38	EPS Q/Q	11.11%	SMA20	-4.54%	Beta	1.12	Target Price	46.80

Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	-100.00%	SMA50	-0.76%	Rel Volume	0.42	Prev Close	27.18

Employees	137	LT Debt/Eq	0.09	Earnings	Aug 04	SMA200	55.64%	Avg Volume	4.01M	Price	27.21

IPO Date	Sep 03, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.01% -	Net Debt/EBITDA	1.19	Volume	1,687,619	Change	0.11%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-17-26	Reiterated	Mizuho	Outperform	$36 → $40
Jun-29-26	Reiterated	Canaccord Genuity	Buy	$42 → $46
Jun-26-26	Upgrade	Jefferies	Hold → Buy	$60
Jun-09-26	Reiterated	HC Wainwright & Co.	Buy	$13 → $66
Jun-09-26	Reiterated	Canaccord Genuity	Buy	$42
Jun-08-26	Reiterated	Mizuho Securities	Outperform	$30 → $36
Jun-08-26	Reiterated	Wolfe Research		$35
Jun-08-26	Reiterated	Leerink Partners	Outperform	$69
May-15-26	Downgrade	Piper Sandler	Overweight → Neutral	$24
May-15-26	Reiterated	Mizuho	Outperform	$19 → $30

Latest News

Jul-22-26

Jul-22-2610:56AM

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%zacks.com

Jul-19-26

Jul-19-2604:01AM

Tango Therapeutics (NASDAQ:TNGX) Trading Up 6.1% – Should You Buy?defenseworld.net

Jul-17-26

Jul-17-2602:59PM

Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40Benzinga

Jul-15-26

Jul-15-2606:59AM

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga

Jul-02-26

Jul-02-2611:51AM

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?zacks.com

11:51AM

Tango Therapeutics Rides a New Precision Oncology Trend in 2026zacks.com

11:46AM

TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalystszacks.com

Jun-29-26

Jun-29-2605:20PM

Biotech Is The Rate Cut Trade In DisguiseSeekingAlpha

Jun-26-26

Jun-26-2609:36AM

Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60Benzinga

Company

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	66	62	42	37	25	37	8	25
Cost of Goods Sold Incl. D&A	1	2	0	0	0	0	2	32
Gross Profit	66	60	42	37	25	37	6	-8
Selling, General and Administrative Excl. Other	42	42	44	36	30	18	8	8
Research and Development	133	132	144	115	106	78	50	32
Other Operating Expense	2	-3	0	0	0	-1	0	-32
Operating Income	-111	-111	-146	-114	-111	-58	-52	-15
Interest Expense	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	10	10	16	13	3	0	0	1
Net Income Before Taxes	-101	-102	-130	-102	-108	-58	-52	-14
Income Taxes	0	0	0	0	0	0	0	0
Consolidated Net Income	-101	-102	-130	-102	-108	-58	-52	-14
Net Income From Continuing Operations	-101	-102	-130	-102	-108	-58	-52	-14
Net Income	-101	-102	-130	-102	-108	-58	-52	-14
EPS (Recurring)	-0.91	-0.87	-1.19	-1.08	-1.23	-0.94	-1.62	-1.57
EPS (Basic, Before Extraordinaries)	-0.91	-0.87	-1.19	-1.08	-1.23	-0.94	-1.62	-1.57
EPS (Diluted)	-0.91	-0.87	-1.19	-1.08	-1.23	-0.94	-1.62	-1.57
EBITDA	-98	-99	-128	-99	-107	-57	-50	-15
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	45.76	16.58	8.02	25.42	25.52	18.33	124.41	—
Gross Margin	100.00	96.77	100.00	100.00	100.00	100.00	75.00	-32.00
Operating Margin	-168.18	-179.03	-347.62	-308.11	-444.00	-156.76	-650.00	-60.00
Net Margin	-153.03	-164.52	-309.52	-275.68	-432.00	-156.76	-650.00	-56.00
Shares Outstanding	111	116	109	95	88	62	87	87
Market Capitalization	3,020	1,028	337	941	638	678	995	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crystal Adam	President, R&D	Jul 01 '26	Option Exercise	5.20	27,000	140,400	142,743	Jul 02
Crystal Adam	President, R&D	Jul 01 '26	Sale	29.59	27,000	798,908	115,743	Jul 02
Crystal Adam	President, R&D	Jun 01 '26	Option Exercise	5.20	27,000	140,400	142,743	Jun 03
Crystal Adam	President, R&D	Jun 01 '26	Sale	22.87	27,000	617,571	115,743	Jun 03
Crystal Adam	President, R&D	May 01 '26	Option Exercise	5.20	27,000	140,400	142,743	May 05
Crystal Adam	President, R&D	May 01 '26	Sale	21.23	27,000	573,097	115,743	May 05
Crystal Adam	President, R&D	Apr 15 '26	Option Exercise	5.20	38,460	199,992	151,082	Apr 16
Crystal Adam	President, R&D	Apr 15 '26	Sale	25.00	38,460	961,500	112,622	Apr 16
Crystal Adam	President, R&D	Apr 01 '26	Option Exercise	5.20	27,000	140,400	139,622	Apr 02
Crystal Adam	President, R&D	Apr 01 '26	Sale	21.20	27,000	572,478	112,622	Apr 02
Crystal Adam	President, R&D	Mar 25 '26	Sale	20.11	12,000	241,320	112,622	Mar 27
Crystal Adam	President, R&D	Mar 25 '26	Option Exercise	5.20	12,000	62,400	124,622	Mar 27
Crystal Adam	President, R&D	Mar 05 '26	Sale	15.00	20,251	303,765	112,622	Mar 09
Crystal Adam	President, R&D	Feb 25 '26	Sale	12.77	54,345	694,208	132,873	Feb 27
Beckman Daniella	Chief Financial Officer	Feb 03 '26	Sale	12.26	10,317	126,530	184,297	Feb 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.